Endologix second-quarter total revenue increases 19% to $15.7 million
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010.